Hims & Hers Health Inc. Stock News

I see a clear path for Hims & Hers Health to reach $100 a share, and I plan to be there when it gets there. HIMS expects revenue growth to rebound, driven by weight loss and new health offerings, aiming for 30%+ growth in 2026. Despite a temporary dip into negative free cash flow, HIMS maintains strong profitability targets and trades at an attractive 24x forward free cash flow.

This options trade set up a potential buying of volatile Hims & Hers Health stock at a discount.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today published a new white paper - Understanding Hims & Hers Approach to Clinical Excellence, Quality, and Safety - detailing how rigorous standards, continuous monitoring, and customer-centered design are shaping the future of safe and effective telehealth. “At Hims & Hers, we believe that digital healthcare must be both ac...

Hims & Hers is driving growth through holistic treatment plans, strategic pharma partnerships, and expanded prescription offerings to boost revenue per subscriber. HIMS' recent partnership with Marius Pharmaceuticals for Kyzatrex positions it to capture a larger share of the growing testosterone therapy market and cross-sell to existing users. Despite premium valuation multiples, HIMS maintains...

Hims stock is near a buy point of 60.55 in a cup-with-handle base. The IBD 50 growth stock has gained 126% year-to-date.

The market often gets worried when a company announces a major change in its C-suite. On news that it was doing just that, on Friday the stock of consumer healthcare company Hims & Hers (HIMS -9.05%) was whacked with a more than 9% sell-off by investors.

PHILADELPHIA , Oct. 3, 2025 /PRNewswire/ --  Berger Montague , a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its p...

Hims & Hers stock (NASDAQ: HIMS) has recently witnessed a remarkable rebound, climbing 42% over the last month from approximately $42 to its current price of $59. This significant increase is primarily due to the announcement that a U.S. federal judge dismissed a lawsuit brought by Eli Lilly against a rival telehealth company, Willow Health, on September 2, 2025.